On December 31, 2025, Salarius Pharmaceuticals, Inc. reconvened its Annual Meeting where 39.7% of stockholders voted to re-elect two directors and ratify Ernst & Young as auditors, with 1,051,782 shares outstanding; the proposal to approve executive compensation received 132,240 votes for and 22,606 against.